Medical network - April 24 people club department released "about open for establishing the basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue dynamic adjustment mechanism announcement concerning the opinion suggestion, including" exit mechanism "medicare drugs directory drugs cause extensive attention from all walks of life. If the 2009 version of the medical insurance directory for shortlisted varieties nearly 8 years, dividends, interests so shortlisted for the 2017 version of the health insurance directory of variety, or "risk" faces at any time be paged out. 

 

Experts say, poor dynamic adjustment mechanism of curative effect of treatment of drugs and auxiliary class medicine, most affected, with some places has already started to focus on auxiliary class drug regulation, and drug zero bonus policy is expected to be rolled out across the country before the second half of this year, auxiliary medication or will be affected bear the brunt. 

 

▍ into health care or is no longer "iron rice bowl"? 

 

For a long time, into the health care means that picked up the biggest domestic medical market sales "stabilizer". 

 

, according to data from the kang CMH 2015, scale level hospital drug market in China has up to 998.5 billion yuan, accounting for the domestic pharmaceutical market (excluding retail medicine) 72.5% of the total, 2016 grade hospital drug market is to point to will exceed 1 trillion yuan. 

 

Because of this, medical insurance directory and huge market, is of vital significance to drug companies. With kang pharmaceutical toxic heat of ning injection, for example, in 2009, sales income is 198 million yuan, only after 2010 into the national health insurance directory, through several years of rapid peatlands, 2015 annual sales income is 1.4 billion yuan. This reflects couldn't enter into the medical insurance directory, drug sales may differ anecdotal, 10 times is not nonsense. 

 

This "notice", apparently beyond the expectation of the industry. SMW reporter noticed that the domestic relevant association and drug firms have focused on this matter. 

 

"This comment is quite open, people club department gave no forming draft, but gives a series of problems, it is very rare." China association of enterprises with foreign investment in drug research and development industry committee (RDPAC) according to one director. He said to the reporter, RDPAC transfer files to member companies, has been the first time in May is expected to form the final recommendations based on member companies consensus. 

 

▍ some auxiliary medication will bear the brunt 

 

In southeast university health care experts zhang point of view, health is a kind of current financing, need to manage according to fund condition, and evaluate the project. Once the dynamic adjustment mechanism is established, the drug into the medical insurance directory will not once and for all things. 

 

If a formal form "directory dynamic adjustment mechanism, therapeutic drugs must be paged out. This part of the medical cost will be transferred to the patients with or at the hospital." Zhang believes that given drug zero bonus will fully implement this year, because for hospitals and doctors prescribing incentive, hospitals and doctors on complementary medicine dynamics will decline. 

 

The past 15% of drug addition, to a certain extent, promote the medical institution for supporting the use of drugs. But as the country of a slowdown in the health care financing, public hospital drugs zero bonus has been clear about the execution date. 

 

Earlier, in response to the medical insurance pay pressure increases year by year, in 2015 Beijing took the lead in order to make clear the administrative measures for auxiliary medicine to standardize the management, 14 domestic provinces and cities related policies, specific to the key regulatory or restrict the use of adjuvant. Affected by this, a batch of within the scope of medical insurance directory, the sales amount is blockbuster drugs have been covered. 

 

Group factors ginseng and astragalus injection method, for example, its 2016 sales of 1.679 billion yuan, up 9.31% from a year earlier, the growth is lower than 17.2% for 2015. And, according to public information zhongheng group from 2012 to 2014, injection with thrombosis through series products annual sales of 2.61 billion yuan. In 2015, however, after the auxiliary medicine catalogue, around the injection with thrombus is fell. According to zhongheng group 2016 half annals, thrombus reduced about 18.70% compared to the same series products sales. 

 

▍ innovation medicine will benefit? 

 

"According to the statement notification, the future of Chinese health care a similar dynamic adjustment in the United States, is the trend of The Times." The general manager of guangzhou pharmaceutical company Liang Feng of SMW reporter said. 

 

According to its introduction, in the United States, medical insurance and commercial insurance companies usually will be according to the survey of the situation of medicine, and based on the results of the survey in talks. And factors that influence the results include not only the cure rate, will also involve drug economics, for example, although the new drug is very expensive, but if bring up medical insurance directory after the consequences will be greater than the burden of expenses for medicine, the drug may be will be included in the list. 

 

Through the "notice", visible people club department of innovative drugs incorporated in the health concerns. "Notice", for example, in the "dynamic adjusting medicare drug directory clinical requirements, how to balance both support innovation and tolerance" medical insurance fund, has already been thrown to relevant associations, drug companies. 

 

Last year start this month, and just start the second batch of pilot health talks, is also thought to be signs of a new health insurance directory support innovation. 

 

It is understood that the first batch of national health insurance directory negotiations, first-line treatment chronic hepatitis b drug tenofovir ester, ek for non-small cell lung cancer targeted therapy drugs, the treatment and 3 kinds of drugs after voluntarily reduce our price by 67%, 67%, 54%, has been included in the health care, recently the second batch of 44 varieties negotiations drugs have also been through "in the form of price change amount" become "green" health insurance directory.